Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

HCRN-GU18-343

A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)

Status: Open to Accrual

Learn more:

Abstracts/Posters/Presentations:

  • D Kilari, A Szabo, KA Bylow, RS Alter, AA Nelson, E Lemke, WA Hall, S Johnson, P Langenstroer, K Jacobsohn, NB Davis, C Fung, MI Milowsky. A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study. Presented as a Trials in Progress Poster at the ASCO 2021 Annual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr TPS4591). See abstract.
  • M Milowsky, N Davis, C Fung, S Johnson, P Langenstroer, K Jacobsohn, K Bylow, D Kilari. A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE). Presented as a Trials in Progress E-Poster at the ESMO 2020 Virtual Congress, Sept. 17, 2020. Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274. See abstract.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.